Tag Archive for: Bispecific Engager of Antigen-presenting cells and T cells

Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform

Automated, closed-system process to support Currus’ Phase 1 trial in mesothelin-positive solid tumours, with first patient dosing expected in early 2027 KINGSTON, Ontario and MELBOURNE, Australia, October 27, 2026 – Octane Biotech Inc. (“Octane”) and Currus Biologics (“Currus”), an Australian biotech developing the BEAT, a proprietary, universal, bispecific antibody platform to unlock CAR T-cell therapy […]

© Optimum Strategic Communications.